Princeton, NJ, United States
Princeton, NJ, United States

Bristol-Myers Squibb, often referred to as BMS, is an American pharmaceutical company, headquartered in New York City.Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Its mission is to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases."BMS' primary R&D sites are located in Lawrence Township and Wallingford, Connecticut , with other sites in Hopewell and New Brunswick, New Jersey, and in Braine-l'Alleud, Belgium, Tokyo, and Bangalore, India. Wikipedia.


Time filter

Source Type

Patent
Bristol Myers Squibb | Date: 2016-12-06

In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.


The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of various disorders of the central nervous system.


Patent
Bristol Myers Squibb | Date: 2016-10-28

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R_(1 )is OH or OP(O)(OH)_(2), and X_(1), X_(2), X_(3), R_(2), R_(2a), R_(a), R_(b), and R_(c )are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P_(1), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.


Patent
Bristol Myers Squibb | Date: 2016-11-17

Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR_(4 )or N; R_(1), R_(2), R_(3), R_(4), and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Brutons tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.


Patent
Bristol Myers Squibb | Date: 2016-11-28

The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.


Benzodiazepine dimers having a structure represented by wherein R^(1 )is wherein the variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used in an antibody-drug conjugate (ADC).


Patent
Bristol Myers Squibb | Date: 2016-08-31

Described herein are methods for maintaining PEGylation and inhibiting dePEGylation of polypeptides, such as fibronectin-based scaffold proteins, during storage.


The present application describes lactam-containing compounds and derivatives thereof of Formula I: P_(4)P-M-M_(4)I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.


Patent
Bristol Myers Squibb | Date: 2017-03-22

The application provides Fc fusion proteins having novel arrangements. In particular, the application provides Fc fusion proteins comprising a ^(10)Fn3 domain and a linker derived from the naturally occurring C-terminal tail regions of membrane bound or secretory immunoglobulins.


Patent
Bristol Myers Squibb | Date: 2017-02-01

A compound of formula I_(1) and R_(24) are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, I_(Kur)-associated disorders, and other disorders mediated by ion channel function.

Loading Bristol Myers Squibb collaborators
Loading Bristol Myers Squibb collaborators